ERBB2 and breast cancer: The efficacy of T-DXd for advanced or metastatic HER2-positive breast cancer after progression on T-DM1 was established in the DESTINY-Breast01 trial [8] and confirmed in the randomised phase 3 DESTINY-Breast02 [9] trial.